RNS60

About Revalesio

Revalesio is a private, clinical-stage biotech founded in 2005 and based in Tacoma, Washington. The company is developing a novel class of drugs using a proprietary fluid physics technology to create charge-stabilized nanostructures (CSN), with its lead program RNS60 in Phase 2 development for ischemic stroke recovery. With a leadership team boasting deep pharmaceutical industry and neurology expertise, Revalesio is targeting significant unmet needs in stroke rehabilitation and age-related neurological disorders, though it faces the inherent risks of clinical development and future capital needs.

Therapeutic Areas

Other Ischemic Stroke Recovery Drugs